India on Wednesday launched its first indigenously manufactured anti-malaria new-age drug Synriam. The drug, produced by Ranbaxy Laboratories, was formally introduced for marketing here.

The drug, launched by Health Minister Ghulam Nabi Azad in the presence of Science and Technology Minister Vilasrao Deshmukh, has been developed by the company in collaboration with the Department of Science and Technology and supported by the Indian Council for Medical Research.

New Delhi: India has developed a powerful new malaria drug — an alternative to the global drug of choice Artemisinin — that promises to be a major boost to India’s pharmaceutical research.

Bombay HC refuses to stay 1996 notice to 500 companies on overcharging for bulk drugs

Mumbai: Japanese drug major Daiichi has lowered its profit forecast for the year ending March 2012, and slashed senior executive pay, to offset the impending loss arising out of its Indian subsidia

The Lipitor incident provides us with some insight into the pharmaceutical world, where science rubs shoulders with greed and intrigue

Cholesterol Drug Hits US Stores The Day Pfizer Loses Patent Protection

Lipitor goes off patent today, but Pfizer may’ve queered pitch for clones, impacting Ranbaxy-led Indian pharma

India’s attempts to check foreign investment in pharma and expand drug pricing control could force multinationals to exit the country, the head of Pfizer India has warned.

Aggressive marketing initiatives by Pfizer Inc may reduce Ranbaxy Laboratories’ earnings from the scheduled launch of its lowcost version of Lipitor, the world’s largest selling drug, in the US by